Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 heterologous Ebola vaccine regimen in infants (Guinea and Sierra Leone)
2021-001331-10Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of zabdeno and Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Primary endpoint: Solicited local and systemic adverse events post-vaccination.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2021-001331-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001331-10.